Kalaris Therapeutics (KLRS) AI Stock Analysis

• Market Cap: $138.25M
• Dividend Yield: N/A
• Average Volume (3M): 136.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: 63.31%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -11.75
• Shares Outstanding: 18,702,417
• 10 Day Avg. Volume: 189,046
• 30 Day Avg. Volume: 136,224
• PEG Ratio: -0.13
• Price to Book (P/B): 0.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.67
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.02
• 1Y Price Target: $16.67
• Price Target Upside: 101.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -3.22
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $9.50 ▲(15.01% Upside)

The score is held back primarily by weak financial performance (no meaningful revenue, larger losses, and accelerating cash burn), despite a debt-free balance sheet. Technicals are constructive with strong trend confirmation across key moving averages, and recent corporate events are supportive due to extended runway and positive early clinical data. Valuation is difficult to anchor given the negative P/E and lack of dividend support.

Positive Factors

Leadership Stability

Securing leadership stability through executive agreements can enhance strategic direction and stakeholder confidence, supporting long-term growth.

Strong Equity Position

A strong equity position with no debt reduces financial risk, providing a stable foundation for future growth and investment in R&D.

Board Expertise

Adding experienced directors like Leone Patterson can enhance governance and strategic oversight, potentially improving financial and operational performance.

Negative Factors

Consistent Net Losses

Ongoing net losses without revenue generation highlight operational inefficiencies and reliance on external funding, posing sustainability challenges.

Negative Cash Flow

Negative cash flow indicates reliance on external financing, which can limit flexibility and increase financial risk if not addressed by revenue growth.

Operational Cost Challenges

Inefficient management of operational expenses impacts profitability and requires strategic cost management to improve financial health.

Kalaris Therapeutics Business Overview & Revenue Model

Company Description

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

How the Company Makes Money

AlloVir makes money primarily through the development and commercialization of its proprietary T cell therapies. The company's revenue model focuses on the successful progression of its clinical trials and eventual regulatory approval, allowing for the marketing and sale of its therapies. Key revenue streams include potential milestone payments and royalties from partnerships with pharmaceutical companies and healthcare providers. AlloVir's earnings are significantly influenced by its ability to advance its clinical pipeline and secure strategic collaborations to support its research and development efforts.

Kalaris Therapeutics Financial Statement Overview

Summary

AlloVir faces significant financial challenges typical of biotech firms in the development phase. The absence of revenue underscores reliance on external funding to sustain operations. While the company has managed to maintain a strong cash position, the ongoing net losses and negative cash flows highlight the need for breakthroughs in product development or revenue generation to achieve financial sustainability.

Income Statement

AlloVir's income statement shows consistent challenges with revenue generation, as the company reported no revenue in the latest periods. This has led to substantial net losses, reflecting the ongoing high costs without offsetting income. The company’s EBIT and EBITDA margins are negative, indicating a significant challenge in managing operational expenses efficiently.

Balance Sheet

The balance sheet reflects a relatively strong equity position with no debt as of the latest report, which is positive. However, the consistent net losses have eroded equity over time. The company’s equity ratio is relatively healthy, indicating a strong reliance on equity financing rather than debt, which reduces financial risk in the near term.

Cash Flow

AlloVir's cash flow statement highlights significant operational cash outflows, reflecting the ongoing operational costs without revenue support. The free cash flow is negative, indicating reliance on external financing or cash reserves for sustainability. However, cash flow from financing activities has helped bolster cash reserves.

Breakdown	TTM	Dec 2024	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	-1.12M
EBITDA	-32.00M	-58.77M	-58.77M	-14.01M	-15.25M	-169.84M
Net Income	-33.44M	-58.77M	-58.77M	-14.70M	-15.48M	-171.96M
Balance Sheet
Total Assets	81.17M	118.55M	118.55M	3.33M	3.90M	286.59M
Cash, Cash Equivalents and Short-Term Investments	77.00M	118.29M	118.29M	3.17M	3.06M	248.12M
Total Debt	1.54M	0.00	0.00	0.00	3.25M	30.07M
Total Liabilities	39.31M	5.24M	5.24M	48.35M	34.17M	61.33M
Stockholders Equity	41.87M	113.31M	113.31M	-45.02M	-30.27M	225.27M
Cash Flow
Free Cash Flow	-33.84M	-67.70M	-67.70M	-14.13M	-9.78M	-106.34M
Operating Cash Flow	-33.66M	-67.70M	-67.70M	-14.13M	-9.78M	-106.32M
Investing Cash Flow	-34.71M	95.00M	95.00M	0.00	0.00	185.98M
Financing Cash Flow	109.61M	21.00K	21.00K	14.24M	12.78M	232.00K

Kalaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Positive. The current price of 8.26 is below the 20-day moving average (MA) of 8.91, above the 50-day MA of 6.94, and above the 200-day MA of 4.93, indicating a neutral trend. The MACD of 0.40 indicates Positive momentum. The RSI at 51.23 is Neutral, neither overbought nor oversold. The STOCH value of 21.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KLRS.

Kalaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KLRS	60 Neutral	$138.25M	-1.12	-63.45%	―	―	63.31%
CLLS	54 Neutral	$324.81M	-13.44	-31.07%	―	158.54%	66.90%
KOD	54 Neutral	$1.63B	-6.46	-207.92%	―	―	-12.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$139.77M	25.45	15.95%	―	448.44%	―
CHRS	47 Neutral	$184.93M	-0.96	―	―	-72.54%	-19972.15%
NKTR	47 Neutral	$842.96M	-5.22	-180.24%	―	-32.79%	36.87%

Kalaris Therapeutics Corporate Events

Kalaris Therapeutics Announces Oversubscribed $50 Million Financing

On December 17, 2025, Kalaris Therapeutics announced it had entered into a securities purchase agreement with a group of institutional accredited and qualified institutional investors for an oversubscribed private placement of common stock and pre-funded warrants expected to raise approximately $50 million in gross proceeds, with closing anticipated around December 19, 2025. The deal, priced at a premium to the recent Nasdaq trading average, involves the sale of 4.2 million common shares at $10.00 each and pre-funded warrants for 800,000 additional shares at $9.9999 each, with the warrants immediately exercisable but subject to ownership caps, and includes registration rights obligating Kalaris to later register the resale of the issued securities. Supported by both new and existing specialist healthcare investors and led by Morgan Stanley, Leerink Partners and William Blair, the financing extends Kalaris’s cash runway into the third quarter of 2027 and is intended to fund continued clinical development of TH103 for neovascular AMD as well as general corporate purposes, strengthening the company’s balance sheet and financial flexibility as it advances its retinal disease pipeline.

The most recent analyst rating on (KLRS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.

Kalaris Therapeutics Announces Positive Phase 1a Trial Data

Kalaris Therapeutics announced on December 17, 2025, positive initial data from its Phase 1a clinical trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The trial showed significant improvements in visual acuity and retinal anatomy, with a mean 10-letter gain in vision and robust reductions in central subfield thickness and fluid, following a single injection. TH103 was generally well-tolerated, with no serious adverse events or dose-limiting toxicities observed, and additional process improvements eradicated earlier instances of mild inflammation. This data supports TH103’s engineered extended intraocular retention and suggests the potential for reduced treatment burden and extended treatment durability, positioning the therapy as a promising advancement in the management of nAMD.

The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.

Kalaris Therapeutics Appoints New CFO Matthew Gall

Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. Gall, with a robust background in financial leadership at iTeos Therapeutics and Sarepta Therapeutics, will also serve as the principal financial officer. His employment agreement includes a base salary, bonus eligibility, stock options, and severance benefits, reflecting the company’s strategic focus on strengthening its financial leadership. This appointment marks a significant shift in the company’s executive team, with Brett Hagan stepping down from his role as principal financial officer but continuing as principal accounting officer.

The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.